newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

  • Cogent Biosciences submitted a New Drug Application (NDA) to the FDA for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) on June 30, 2026.
  • The APEX pivotal trial demonstrated a 65% objective response rate (ORR) per mIWG criteria & 81% ORR per PPR criteria among 81 treated AdvSM patients.
  • The NDA is the third submission for bezuclastinib in six months, with PEAK & SUMMIT reviews ongoing & anticipated Q4 2026 approvals.
  • Clinical data showed rapid & deep reductions in aberrant CD25/CD30 expression, normalization of mast cell morphology & bone marrow cellularity, & improvement in myelofibrosis.
  • Bezuclastinib demonstrated durable activity with a 12-month progression-free survival rate of 79% & an overall survival rate of 87%.
  • Significant reductions in disease markers included ≥50% drops in serum tryptase (89%), bone marrow mast cells (89%), & KIT D816V variant allele frequency (91%).
  • The drug was well-tolerated; most frequent treatment-related adverse events were hair color change (31%), neutropenia (31%), altered taste (28%), thrombocytopenia (25%), & ALT/AST elevations (21%).
  • Cogent established Expanded Access Programs for U.S. patients with systemic mastocytosis or GIST who meet specific criteria.
  • The Board approved inducement equity awards for two new employees under Nasdaq Listing Rule 5635(c)(4) totaling 7,600 options & 7,000 restricted stock units.
  • Forward-looking statements indicate expectations for FDA approvals of bezuclastinib in GIST & NonAdvSM by the fourth quarter of 2026.